


PHARMACEUTICAL 2021



NGM BIOPHARMACEUTICALS INC Rank 157 of 409





PHARMACEUTICAL 2021



NGM BIOPHARMACEUTICALS INC Rank 157 of 409

The relative strengths and weaknesses of NGM BIOPHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NGM BIOPHARMACEUTICALS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 92% points. The greatest weakness of NGM BIOPHARMACEUTICALS INC is the variable Research and Development, reducing the Economic Capital Ratio by 171% points.

The company's Economic Capital Ratio, given in the ranking table, is -57%, being 298% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	308,426
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	42,583
Liabilities, Non-Current	0
Other Assets	6,091
Other Compr. Net Income	-21
Other Expenses	0
Other Liabilities	6,417
Other Net Income	1,346
Property and Equipment	14,526
Research and Development	163,972
Revenues	87,368
Selling, General and Administrative Expense	27,229

Output Variable	Value in 1000 USD
Assets	329,043
Liabilities	49,000
Expenses	191,201
Stockholders Equity	280,043
Net Income	-102,487
Comprehensive Net Income	-102,498
Economic Capital Ratio	-57%